Masarykuv Onkologicky Ustav
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Masarykuv Onkologicky Ustav researchers are evaluating innovative anticoagulation strategies to reduce cancer‑associated clotting risk, including trials of new agents for venous thromboembolism (VTE) in patients with gastrointestinal and genitourinary malignancies.
- Prevention of VTE recurrence in oncology patients
- Comparative safety of novel oral anticoagulants versus standard therapy
- Impact of anticoagulation on overall survival in high‑risk cancer cohorts
With 91 active studies and 58 investigators, the department demonstrates a strong commitment to cardio‑oncology and patient safety.
Digestive System Diseases
Clinical programs focus on targeted therapies for gastrointestinal cancers, such as trials addressing FGFR2b overexpression in gastric tumors and evaluating inhibitors for KRAS G12C mutation in colorectal cancer.
- Advanced gastric and gastro‑esophageal junction adenocarcinoma
- KRAS‑mutated colorectal cancer
- Metastatic pancreatic ductal adenocarcinoma
- FGFR2b‑positive gastric cancer
The site’s multidisciplinary team integrates endoscopy, surgery, and medical oncology to accelerate therapeutic development.
Female Urogenital Diseases and Pregnancy Complications
Research includes precision‑medicine approaches for ovarian and endometrial cancers, with studies on BRCA‑mutated ovarian cancer and immunotherapy for PD‑L1‑positive triple‑negative breast cancer.
- BRCA‑mutated high‑grade serous ovarian cancer
- Advanced endometrial carcinoma with molecular profiling
- Triple‑negative breast cancer expressing PD‑L1
- Fallopian tube and primary peritoneal malignancies
By collaborating with gynecologic oncology specialists, the clinic aims to improve outcomes for women across the disease spectrum.
Male Urogenital Diseases
The department conducts pivotal studies on prostate cancer, including trials for metastatic castration‑resistant prostate cancer and investigations of novel hormonal agents in earlier disease stages.
- Biochemically recurrent prostate cancer
- Metastatic castration‑resistant prostate cancer
- Hormone‑sensitive prostate cancer with high‑risk features
- Combination strategies with androgen deprivation therapy
The site leverages advanced imaging and biomarker analysis to personalize treatment pathways for male patients.
Neoplasms
A broad portfolio addresses solid tumours at advanced stages, testing new immunotherapies, kinase inhibitors, and antibody‑drug conjugates across multiple cancer types, including advanced solid tumors.
- Advanced breast cancer (HR‑positive, HER2‑negative and HER2‑positive)
- Metastatic melanoma, including NRAS‑mutant disease
- Non‑small cell lung cancer with diverse genomic alterations
- Renal cell carcinoma, both clear cell and non‑clear cell subtypes
- Glioblastoma and high‑grade astrocytoma
With 58 investigators, the center integrates translational research to bring laboratory discoveries to the bedside.
Pathological Conditions, Signs and Symptoms
Studies explore symptom management and quality‑of‑life outcomes, such as the impact of depression on cancer prognosis and strategies to mitigate treatment‑related toxicities.
- Cancer‑related depressive disorders
- Management of chemotherapy‑induced neuropathy
- Patient‑reported outcome measures for symptom burden
- Biomarker‑driven diagnostics for early disease detection
The multidisciplinary team includes psycho‑oncology specialists to address the holistic needs of patients.
Mental Disorders
A focused trial evaluates the rapid antidepressant effect of psilocybin compared with ketamine in individuals experiencing depression alongside cancer treatment.
- Psilocybin versus ketamine for cancer‑associated depression
- Psychological support interventions during active therapy
- Anxiety reduction programs for oncology patients
- Long‑term mental health follow‑up after remission
By integrating mental health expertise, the site seeks to improve both emotional well‑being and clinical outcomes.
Unspecified Therapeutic Area
A diverse set of studies spans rare and hard‑to‑treat cancers, evaluating novel agents where standard therapy is lacking, and ensuring access to cutting‑edge treatments for patients with unmet needs.
- Rare sarcomas such as dedifferentiated liposarcoma
- High‑risk early‑stage breast cancer in adjuvant settings
- Immune‑checkpoint combinations in tumors without approved options
- Adaptive platform trials for multiple solid tumour histologies
The clinic’s flexible infrastructure supports rapid initiation of innovative protocols across therapeutic domains.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 186 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 186 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 27 by active trials.
- 1Merck Sharp & Dohme LLC14active
lock +26 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC21trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Masarykuv Onkologicky Ustav
lock Showing 1 of 105 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 186 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 24 | Unknown | 2018-08-24 | 2026-07-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.